Sarilumab use in severe Coronavirus Disease 2019 pneumonia

Bibliographic Details
Title:	Sarilumab use in severe Coronavirus Disease 2019 pneumonia
Authors:	Ahmed M.A. El Fattah Amer, Doaa B Mousa
Source:	Egyptian Journal of Chest Disease and Tuberculosis, Vol 72, Iss 2, Pp 191-193 (2023)
Publisher Information:	Wolters Kluwer Medknow Publications, 2023.
Publication Year:	2023
Collection:	LCC:Diseases of the respiratory system
Subject Terms:	coronavirus, interleukin-6, sarilumab, Diseases of the respiratory system, RC705-779
More Details:	Background Interleukin-6 (IL-6) signal blockers have an important role in the management of Coronavirus Disease 2019 (COVID-19) and prevent progression of inflammation. Many studies have evaluated the efficacy of Sarilumab in severe COVID-19 pneumonia. Aim Evaluation of sarilumab efficacy in severe COVID-19 pneumonia. Patients and methods In all, 40 patients with severe acute respiratory syndrome coronavirus 2 severe pneumonia received intravenous sarilumab 400 mg. Results Patients were admitted to the ICU with a mean duration of 18.17 ± 8.75 days. Eighteen (45%) patients on high-flow oxygen with nonrebreather masks and 22 (55%) patients on mechanical ventilation received sarilumab. IL-6 level is with a mean of 62.50 ± 23.01 before sarilumab and a mean of 31.35 ± 33.30 after sarilumab. Thirteen (32.5%) patients improved and 27 (67.5%) patients died. No sarilumab serious adverse effects were detected in this study. Patient oxygen saturation on discharge mean was 95.75±.97%. Concerning serum IL-6 levels among the recruited patients, there was statistically significant difference between the mean baseline level compared with the follow-up levels, 62.50 ± 23.01 and 31.35 ± 33.30 ng/ml, respectively, with a P value of 0.001. Conclusion Sarilumab improves IL-6 level in COVID-19 patients with severe pneumonia with no serious adverse effects. Mortality rate increased in severe COVID-19 cases, so early use of sarilumab in moderate cases may decrease disease progression and decrease mortality rate.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	0422-7638 2090-9950
Relation:	http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2023;volume=72;issue=2;spage=191;epage=193;aulast=El; https://doaj.org/toc/0422-7638; https://doaj.org/toc/2090-9950
DOI:	10.4103/ecdt.ecdt_77_22
Access URL:	https://doaj.org/article/2d1d106b074140f886800f33315e37e0
Accession Number:	edsdoj.2d1d106b074140f886800f33315e37e0
Database:	Directory of Open Access Journals

More Details
ISSN:	04227638 20909950
DOI:	10.4103/ecdt.ecdt_77_22
Published in:	Egyptian Journal of Chest Disease and Tuberculosis
Language:	English